The Oculocerebrorenal Syndrome of Lowe

Steven G. Coca, Robert F. Reilly

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The oculocerebrorenal syndrome of Lowe (OCRL) is a rare human X-linked disorder manifested clinically by congenital cataracts, severe mental retardation, and renal tubular dysfunction (Fanconi's syndrome). Several mutations, including truncation mutations (nonsense, splicesite, frame-shift), missense and occasionally, somatic mutations have been identified as causative for OCRL. Nucleotide mutations are concentrated in the 3' part of the gene, whereas most of the large genomic deletions occur in the 5' part of the gene. Ninety-three percent of mutations are concentrated in only half of the 24 exons. Fifty-two percent of mutations are in five exons, and 20% have mutations in exon 15. The gene product of OCRL1, referred to as ocrl1, a 105 kD protein, deficient in Lowe syndrome, was identified to be the enzyme phosphatidylinositol-4,5-biphosphate 5-phosphatase. A variety of mutations of the OCRL1 gene lead to a loss of function of its product, the enzyme phosphatidylinositol (4,5) biphosphate 5-phosphatase (orcl1), which leads to accumulation of phosphatidylinositol (4,5) biphosphate. Most patients with OCRL have some degree of mental retardation, most with moderate to severe impairment. A small percentage of individuals (10%) have IQs in the normal or borderline range. OCRL results in proximal tubule dysfunction (Fanconi syndrome) and progressive renal failure. The onset of renal dysfunction usually is manifest a few weeks to months after birth, presenting with renal tubular acidosis, proteinuria, phosphaturia, and aminoaciduria and carnitine wasting. Most patients with OCRL have proteinuria, with almost two-thirds having nephrotic range proteinuria, but do not have other characteristics of the nephrotic syndrome.

Original languageEnglish (US)
Title of host publicationGenetic Diseases of the Kidney
PublisherElsevier Inc.
Pages587-596
Number of pages10
ISBN (Print)9780124498518
DOIs
StatePublished - 2009

Fingerprint

Oculocerebrorenal Syndrome
Phosphatidylinositol 4,5-Diphosphate
Genes
Exons
Mutation
Phosphoric Monoester Hydrolases
Proteinuria
Fanconi Syndrome
Carnitine
Intellectual Disability
Enzymes
Familial Hypophosphatemia
Renal Tubular Acidosis
Nucleotides
Kidney
Nonsense Codon
Nephrotic Syndrome
Cataract
Renal Insufficiency
Parturition

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Coca, S. G., & Reilly, R. F. (2009). The Oculocerebrorenal Syndrome of Lowe. In Genetic Diseases of the Kidney (pp. 587-596). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-449851-8.00034-6

The Oculocerebrorenal Syndrome of Lowe. / Coca, Steven G.; Reilly, Robert F.

Genetic Diseases of the Kidney. Elsevier Inc., 2009. p. 587-596.

Research output: Chapter in Book/Report/Conference proceedingChapter

Coca, SG & Reilly, RF 2009, The Oculocerebrorenal Syndrome of Lowe. in Genetic Diseases of the Kidney. Elsevier Inc., pp. 587-596. https://doi.org/10.1016/B978-0-12-449851-8.00034-6
Coca SG, Reilly RF. The Oculocerebrorenal Syndrome of Lowe. In Genetic Diseases of the Kidney. Elsevier Inc. 2009. p. 587-596 https://doi.org/10.1016/B978-0-12-449851-8.00034-6
Coca, Steven G. ; Reilly, Robert F. / The Oculocerebrorenal Syndrome of Lowe. Genetic Diseases of the Kidney. Elsevier Inc., 2009. pp. 587-596
@inbook{b58f90038515444c8d69895fca9768e4,
title = "The Oculocerebrorenal Syndrome of Lowe",
abstract = "The oculocerebrorenal syndrome of Lowe (OCRL) is a rare human X-linked disorder manifested clinically by congenital cataracts, severe mental retardation, and renal tubular dysfunction (Fanconi's syndrome). Several mutations, including truncation mutations (nonsense, splicesite, frame-shift), missense and occasionally, somatic mutations have been identified as causative for OCRL. Nucleotide mutations are concentrated in the 3' part of the gene, whereas most of the large genomic deletions occur in the 5' part of the gene. Ninety-three percent of mutations are concentrated in only half of the 24 exons. Fifty-two percent of mutations are in five exons, and 20{\%} have mutations in exon 15. The gene product of OCRL1, referred to as ocrl1, a 105 kD protein, deficient in Lowe syndrome, was identified to be the enzyme phosphatidylinositol-4,5-biphosphate 5-phosphatase. A variety of mutations of the OCRL1 gene lead to a loss of function of its product, the enzyme phosphatidylinositol (4,5) biphosphate 5-phosphatase (orcl1), which leads to accumulation of phosphatidylinositol (4,5) biphosphate. Most patients with OCRL have some degree of mental retardation, most with moderate to severe impairment. A small percentage of individuals (10{\%}) have IQs in the normal or borderline range. OCRL results in proximal tubule dysfunction (Fanconi syndrome) and progressive renal failure. The onset of renal dysfunction usually is manifest a few weeks to months after birth, presenting with renal tubular acidosis, proteinuria, phosphaturia, and aminoaciduria and carnitine wasting. Most patients with OCRL have proteinuria, with almost two-thirds having nephrotic range proteinuria, but do not have other characteristics of the nephrotic syndrome.",
author = "Coca, {Steven G.} and Reilly, {Robert F.}",
year = "2009",
doi = "10.1016/B978-0-12-449851-8.00034-6",
language = "English (US)",
isbn = "9780124498518",
pages = "587--596",
booktitle = "Genetic Diseases of the Kidney",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - The Oculocerebrorenal Syndrome of Lowe

AU - Coca, Steven G.

AU - Reilly, Robert F.

PY - 2009

Y1 - 2009

N2 - The oculocerebrorenal syndrome of Lowe (OCRL) is a rare human X-linked disorder manifested clinically by congenital cataracts, severe mental retardation, and renal tubular dysfunction (Fanconi's syndrome). Several mutations, including truncation mutations (nonsense, splicesite, frame-shift), missense and occasionally, somatic mutations have been identified as causative for OCRL. Nucleotide mutations are concentrated in the 3' part of the gene, whereas most of the large genomic deletions occur in the 5' part of the gene. Ninety-three percent of mutations are concentrated in only half of the 24 exons. Fifty-two percent of mutations are in five exons, and 20% have mutations in exon 15. The gene product of OCRL1, referred to as ocrl1, a 105 kD protein, deficient in Lowe syndrome, was identified to be the enzyme phosphatidylinositol-4,5-biphosphate 5-phosphatase. A variety of mutations of the OCRL1 gene lead to a loss of function of its product, the enzyme phosphatidylinositol (4,5) biphosphate 5-phosphatase (orcl1), which leads to accumulation of phosphatidylinositol (4,5) biphosphate. Most patients with OCRL have some degree of mental retardation, most with moderate to severe impairment. A small percentage of individuals (10%) have IQs in the normal or borderline range. OCRL results in proximal tubule dysfunction (Fanconi syndrome) and progressive renal failure. The onset of renal dysfunction usually is manifest a few weeks to months after birth, presenting with renal tubular acidosis, proteinuria, phosphaturia, and aminoaciduria and carnitine wasting. Most patients with OCRL have proteinuria, with almost two-thirds having nephrotic range proteinuria, but do not have other characteristics of the nephrotic syndrome.

AB - The oculocerebrorenal syndrome of Lowe (OCRL) is a rare human X-linked disorder manifested clinically by congenital cataracts, severe mental retardation, and renal tubular dysfunction (Fanconi's syndrome). Several mutations, including truncation mutations (nonsense, splicesite, frame-shift), missense and occasionally, somatic mutations have been identified as causative for OCRL. Nucleotide mutations are concentrated in the 3' part of the gene, whereas most of the large genomic deletions occur in the 5' part of the gene. Ninety-three percent of mutations are concentrated in only half of the 24 exons. Fifty-two percent of mutations are in five exons, and 20% have mutations in exon 15. The gene product of OCRL1, referred to as ocrl1, a 105 kD protein, deficient in Lowe syndrome, was identified to be the enzyme phosphatidylinositol-4,5-biphosphate 5-phosphatase. A variety of mutations of the OCRL1 gene lead to a loss of function of its product, the enzyme phosphatidylinositol (4,5) biphosphate 5-phosphatase (orcl1), which leads to accumulation of phosphatidylinositol (4,5) biphosphate. Most patients with OCRL have some degree of mental retardation, most with moderate to severe impairment. A small percentage of individuals (10%) have IQs in the normal or borderline range. OCRL results in proximal tubule dysfunction (Fanconi syndrome) and progressive renal failure. The onset of renal dysfunction usually is manifest a few weeks to months after birth, presenting with renal tubular acidosis, proteinuria, phosphaturia, and aminoaciduria and carnitine wasting. Most patients with OCRL have proteinuria, with almost two-thirds having nephrotic range proteinuria, but do not have other characteristics of the nephrotic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=79954429259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954429259&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-449851-8.00034-6

DO - 10.1016/B978-0-12-449851-8.00034-6

M3 - Chapter

AN - SCOPUS:79954429259

SN - 9780124498518

SP - 587

EP - 596

BT - Genetic Diseases of the Kidney

PB - Elsevier Inc.

ER -